Condition: Gene Mutations · Pseudoxanthoma Elasticum · Arterial Calcification · Sponsor: Inozyme Pharma
The purpose of this study (Study INZ701-304 \[ADAPT\]) is to assess the long-term safety of INZ-701 in patients with ENPP1 Deficiency or ABCC6 Deficiency who have received INZ-701 in an existing clinical study and choose to continue dosing for the potential treatment of their condition.
This description comes directly from the study's public registry record.
Inozyme Clinical Trial Information · +1 857 330 4340 · clinicaltrials@inozyme.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Clinilabs Drug Development Corporation | Eatontown, New Jersey, United States | Recruiting |
| Necker-Enfants Malades Hospital | Paris, France | Recruiting |
| Universitätsklinikum Hamburg-Eppendorf (UKE) | Hamburg, Germany | Recruiting |
| VCTC | Oxford, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06462547